Table 2.

Associations between patient and tumour characteristics and treatment approach in 363 patients diagnosed with glioblastoma between January 2007 and December 2014

	No resection				CRT less intensive than Stupp protocol†
	Unadjusted		Adjusted		Unadjusted		Adjusted
	OR	(95% CI)	OR	(95% CI)	OR	(95% CI)	OR	(95% CI)
Female gender	1.1	(0.7 to 1.6)	1.0	(0.6 to 1.7)	1.7	(1.1 to 2.5)*	1.8	(1.1 to 3.1)*
Age ≥70 years	4.5	(2.9 to 7.2)***	3.0	(1.5 to 6.3)**	13.7	(7.3 to 25.8)***	5.1	(2.2 to 11.8)***
Cognitive impairment	1.2	(0.8 to 1.8)	1.2	(0.8 to 2.1)	1.8	(0.6 to 1.7)**	1.8	(1.1 to 3.0)*
Charlson Comorbidity Index	1.5	(1.3 to 1.8)***	1.3	(1.0 to 1.6)*	2.2	(1.8 to 2.6)***	1.6	(1.2 to 2.0)***
Multifocal tumour	1.9	(1.2 to 3.1)**	2.6	(1.5 to 4.6)*	1.2	(0.7 to 1.9)	1.6	(0.9 to 2.9)
Deep-seated tumour‡	7.3	(3.5 to 15.3)***	10.0	(4.4 to 22.3)***	1.4	(0.7 to 2.6)	1.5	(0.7 to 3.2)

Significant p values are in bold.

*Two-sided p values <0.05 were considered statistically significant; *p<0.05; **p<0.01; ***p<0.001; results not marked by an asterisk are not significant.

†Stupp protocol=radiation therapy 60 Gy in 2 Gy fractions (delivered), fulfilled concomitant TMZ and fulfilled at least one out of six planned TMZ monotherapy courses.

‡Thalamus, basal ganglia, internal capsule, splenium corpus callosum, mesencephalon, brain stem and cerebellum.

CRT, chemoradiotherapy; TMZ, temozolomide.